Two red rose hips with water droplets on a sprig

Research

Rosehip: what is behind the vitamin C reputation

13 min read

The rosehip has a reputation that comes from childhood: lots of vitamin C, rosehip tea, good for a cold. That reputation is not wrong - but it conceals what research is actually interested in about this fruit, and it misleads when it comes to judging a product. This article places what has been studied on rosehip, where the data are solid and where they expressly are not.

What is the rosehip botanically?

Rosehips are the fruits of wild roses. Botanically they are not berries but aggregate fruits: what looks red and fleshy is the thickened floral base; the actual fruits are the small hairy nutlets inside.

Whole and halved rose hip with visible achenes on white
Rose hips are rich in vitamin C, but across 11 dog rose provenances the content ranged from 103.5 to 419.7 mg per 100 g dry weight.

In products and in herbal medicine, the dog rose is usually used, Rosa canina - the wild rose that glows at woodland edges and in hedgerows in autumn. Depending on the preparation, what is processed is the whole fruit, the flesh alone without seeds, or an extract of it. This distinction is no trifle, as will become clear.

How much vitamin C is in rosehips?

Rosehips contain a lot of vitamin C - that is true. The only question is: exactly how much?

The vitamin C reputation is correct - and still misleads when it comes to judging a product.

An investigation of 11 provenances of dog rose from Iran found contents between 103.5 and 419.7 mg per 100 g dry weight.1 That is more than fourfold between the poorest and the richest sample - within the same plant species. For the red pigments (anthocyanins) the range of 0.98 to 4.41 mg was even wider; for seed oil, polyphenols and carotenoids it was about twofold.1

Dog rose: how much 11 provenances of the same species vary

Highest divided by lowest content, based on dry weight

Anthocyanins0.98-4.41 mg per 100 gfactor 4.5
Vitamin C103.5-419.7 mg per 100 gfactor 4.1
Seed oil8.1-16.9 % of seedsfactor 2.1
Total polyphenols52.9-104.5 mg per gfactor 2.0
Total carotenoids111-207 mg per gfactor 1.9
Total flavonoids14.2-25.2 mg per gfactor 1.8
Source: Bakhtiar et al. 2023, 11 provenances of Rosa canina from Iran. A factor of 4.1 means the richest sample contained just over four times as much as the poorest.

More instructive still is a comparison across several roses. There, another wild rose species, Rosa sweginzowii, and the cultivar 'Fru Dagmar Hastrup' reached ascorbic acid contents of 4,711 and 4,325 mg per 100 g dry weight. The authors state expressly that the traditionally used Rosa canina had the reddest fruit but did not stand out in most other parameters.2

From this follows an uncomfortable but useful insight: without an analysis, the word "rosehip" says practically nothing about the vitamin C content. Tradition selected the dog rose, not measurement.

Which plant compounds does rosehip contain besides vitamin C?

The research of the past 20 years is less interested in the vitamin than in other constituents. A review of rosehip in joint complaints names 2 groups: a galactolipid with the abbreviation GOPO, isolated from flesh and seeds, and a mixture of triterpene acids - ursolic acid, oleanolic acid and betulinic acid.3

Anti-inflammatory properties have been described for these substances in laboratory experiments.3 As with all such findings: that is a starting point for studies in humans, not a result.

Then there are polyphenols. In the Iranian samples, catechin was the most abundant single compound. The EGCG from green tea belongs to the same group.1 In the comparison of roses, flavanols were the main group, including catechin and proanthocyanidin compounds of the kind also found in OPC from grape seeds.2

What do studies show on rosehip in osteoarthritis?

The best-studied area of use is joint pain in osteoarthritis. A meta-analysis summarised 3 randomised, placebo-controlled trials (comparison studies in which chance assigns the groups and one group receives a dummy preparation) with 287 patients in total and a mean duration of 3 months. The result: a reduction in pain with an effect size of 0.37 (95 % confidence interval 0.13 to 0.60; p = 0.002). The number of patients who have to be treated for one additional person to respond was 6.4

That is a measurable but moderate effect - and it deserves 3 qualifications, all of which appear in the same meta-analysis or in the follow-up studies.

Rosehip in osteoarthritis: what the studies show

Randomised, placebo-controlled trials and their summary

Meta-analysis, 3 trials287 patients, effect size 0.37, all manufacturer-fundedmoderate effect
Cross-over trial, 5 g powder112 patients, difference in one sequence onlymixed
Largest single trial120 patients, both groups more than 50 % betterno difference
Subsequent dose analysisrelationship in the active group onlyhypothesis
Combination with devil's claw92 patients, share of rosehip unclearnot attributable
Sources: Christensen et al. 2008, Rein et al. 2004, Motawei et al. 2026, Moré et al. 2017. A measured effect is not an authorised health claim.

What are the limits of the evidence?

First: all 3 studies were funded by the manufacturer. The authors of the meta-analysis write that themselves in the abstract and call for independent replication in a larger, longer study.4

That does not devalue the data, but it belongs alongside them. A Cochrane review of 75 methodological studies on drug and medical device trials found that trials funded by the manufacturing company more often report favourable efficacy results (risk ratio 1.27; 95 % CI 1.17 to 1.37) and more often draw favourable conclusions (1.34; 1.19 to 1.51) than trials with other funding. Notably, this difference could not be explained by the usual instruments for assessing risk of bias.5

Second: the largest single study found no difference in the main comparison. In a multicentre investigation with 120 patients with hip or knee osteoarthritis, both groups improved by more than 50 per cent - the one with standardised rosehip powder and the one with a dummy preparation. No statistically significant difference between the groups emerged. Only a re-analysis published in 2026, correlating dose per kilogram of body weight with improvement, showed a relationship, and only in the active group.6

This post-hoc analysis is methodologically interesting, but it is something other than a positive main result. A secondary, exploratory evaluation generates hypotheses; it does not establish them.

It is notable that this pattern is not new. The oldest of the 3 studies in the meta-analysis - a cross-over trial with 112 patients who received 5 grams of standardised rosehip powder or a dummy preparation daily - showed it in another form: the group that began with the dummy preparation clearly benefited from the switch to the powder. In the group that began the other way round, the dummy preparation subsequently worked similarly well. The authors interpreted that as an after-effect of the powder.7 In the first 3 months, 31 of 47 patients responded on powder (66 per cent) and 18 of 50 on the dummy preparation (36 per cent).7

Response in the first 3 months of the cross-over trial

Share of patients with less joint pain

Rosehip powder, 5 g a day31 of 4766 %
Dummy preparation18 of 5036 %
Source: Rein et al. 2004, 112 patients, manufacturer-funded. More than a third also responded to the dummy preparation.

The after-effect is one possible explanation. A second, which cannot be excluded: part of the improvement observed arose through expectation. With pain, a lot often improves on a dummy preparation too - by more than 50 per cent in the study with 120 patients.6 That is exactly where the difficulty lies in cleanly demonstrating a moderate effect on this endpoint.

Third: rosehip is usually not tested on its own. A randomised study with 92 patients with knee osteoarthritis found, for a combination of rosehip, nettle, devil's claw and vitamin D, a clear improvement in the WOMAC pain score compared with placebo (minus 29.9 against minus 10.2 points; p < 0.001).8 Only: this combination contains, in devil's claw, a component that is itself well studied in joint complaints. What share the rosehip has in the result, the study does not say.

The same pattern shows in other areas of use: in ADHD as an add-on to standard medication9 and in chronic tinnitus10 - each time in combinations or alongside a standard treatment, each time without the possibility of cleanly separating out the individual contribution.

Why does "extract" say little without standardisation?

Here lies the point that helps most in judging a product - and that is most often overlooked.

A plant extract is not a defined substance but the result of a process. How much starting material is in one gram of extract depends on the extraction ratio; that can mean 4:1 or 50:1. And how much of the substance of interest is in it depends on the solvent, the plant part and the batch.

That is why a statement such as "60 mg extract" is not comparable on its own - neither with another preparation nor with a study dose. Only standardisation makes it so: the statement of which characteristic plant compound and which content the extract is adjusted to.

That is exactly what the review cited calls for in future research: further clinical studies on standardised rosehip preparations.3 The gap is therefore not an invention of this article but is named in the specialist literature.

The clinical studies on osteoarthritis worked with 5 grams of rosehip powder daily.7 Whether an amount of extract in the milligram range comes close to that simply cannot be calculated without the extraction ratio.

What makes a rosehip amount comparable

3 pieces of information without which no amount can be compared with a study

Formpowder from the fruit or extract, plant partpowder in the trials
Extraction ratiohow much plant is in 1 part of extractfor example 4:1 or 50:1
Standardisationto which plant compound, at what contentoften missing
Study amount for comparisonosteoarthritis trials, daily5 g powder
Sources: Rein et al. 2004 (5 g daily), Pekacar et al. 2021 (call for trials on standardised preparations). The ratios 4:1 and 50:1 are examples.

How does a smaller amount fit into this picture?

Soberly considered: from an amount of rosehip of the kind found in comprehensive micronutrient products, no pain relief in osteoarthritis is to be expected. The studies that found something worked with gram amounts of a powder, not with milligrams of an extract.

As a source of vitamin C it also contributes little in such products, because vitamin C there is declared separately and in a defined amount anyway. A natural content that varies fourfold would be unsuitable for a reliable declaration in any case.

What remains is the role as one of several plant components with natural pigments (carotenoids), plant compounds (polyphenols) and organic acids - not an active substance in the pharmacological sense, but part of a selection. That is a more honest description than any claim of effect resting on studies with eighty times the amount.

How safe is rosehip?

Rosehip has been consumed as a food for centuries - as tea, purée, jam and soup. In the clinical studies, tolerability was unremarkable; in the cross-over trial, no major side effects occurred in either group.7 The meta-analysis urges that safety, like efficacy, should be examined in larger studies.4

Glass cup of rose hip tea with fresh rose hips and rose sprigs
Rose hip has been eaten for centuries as tea, purée and jam; in processed products the irritating hairs are removed.

One practical note concerns preparation: the fine hairs around the seeds are mechanically irritating - hence the children's joke with "itching powder". In processed products they are removed.

Is there an authorised health claim for rosehip?

For rosehip there is no authorised health claim in the European Union. That does not mean an effect was examined and refuted - it means that no application reached the required burden of proof, or that none was made.

For a substance with a moderate but manufacturer-funded evidence base and a larger study without a main result, that is understandable. How the procedure works and how an assessed statement can be told from an unassessed one is set out in detail here: EU health claims - how to tell whether an effect has been assessed.

Conclusion

The rosehip is better studied than most traditional medicinal plants and still more weakly supported than its reputation suggests. The best evidence concerns joint pain, it comes from manufacturer-funded studies, and the largest single study found nothing in the main comparison.

Its best-known merit - the vitamin C content - is real, but so variable that without an analysis it carries no statement. And the decisive question with any product is not whether rosehip is included, but in what form, at what extraction ratio and standardised to which characteristic plant compound.

Anyone who cannot find these 3 pieces of information cannot compare the amount with any study. That is no argument against the ingredient - it is an argument for looking more closely.

Key takeaways

  • The vitamin C content varies fourfold between provenances of the same species - and in a comparison of several roses, the dog rose stood out mainly for its red colour.
  • The best evidence concerns osteoarthritis pain: a meta-analysis of 3 studies with 287 patients, effect size 0.37, number needed to treat 6.
  • All 3 studies were manufacturer-funded - the authors write it themselves and call for independent replication.
  • The largest single study found no difference in the main comparison. 120 patients, both groups improving by more than 50 per cent; only a subsequent dose-response analysis showed a relationship.
  • "60 mg extract" is not comparable without standardisation - neither with another preparation nor with a study dose. The specialist literature names the same gap.
  • No authorised health claim. That means "not sufficiently established", not "refuted".

Sources

  1. Bakhtiar Z, Eghlima G, Hatami M, Mirjalili MH. Quantification of fatty acids in seed oil and important bioactive compounds in Iranian Rosa canina L. ecotypes for potential cosmetic and medicinal uses. Scientific Reports, 2023.
  2. Cunja V, Mikulic-Petkovsek M, Weber N et al. Fresh from the Ornamental Garden: Hips of Selected Rose Cultivars Rich in Phytonutrients. Journal of Food Science, 2016.
  3. Pekacar S, Bulut S, Özüpek B, Orhan DD. Anti-Inflammatory and Analgesic Effects of Rosehip in Inflammatory Musculoskeletal Disorders and Its Active Molecules. Current Molecular Pharmacology, 2021.
  4. Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H. Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? A meta-analysis of randomized controlled trials. Osteoarthritis and Cartilage, 2008.
  5. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews, 2017.
  6. Motawei AM, Warholm KM, Winther K. Using Dose-Response Correlation Re-Analyzing to Distinguish Placebo from Standardized Rose-Hip Powder (Lito) in a Clinical Trial on Osteoarthritis Where Data Initially Looked Identical. Nutrients, 2026.
  7. Rein E, Kharazmi A, Winther K. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis - a double-blind, placebo-controlled, randomised trial. Phytomedicine, 2004.
  8. Moré M, Gruenwald J, Pohl U, Uebelhack R. A Rosa canina - Urtica dioica - Harpagophytum procumbens/zeyheri Combination Significantly Reduces Gonarthritis Symptoms in a Randomized, Placebo-Controlled Double-Blind Study. Planta Medica, 2017.
  9. Golsorkhi H, Montazerlotfelahi H, Abniki E et al. Efficacy and Safety of Rosa canina L. and a Traditional Polyherbal Formulation Syrup in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Phytotherapy Research, 2025.
  10. Khosravi MH, Atefi A, Mehri A et al. Therapeutic effects of Rosa canina, Urtica dioica and Tanacetum vulgare herbal combination in treatment of tinnitus symptoms: A double-blind randomised clinical trial. Clinical Otolaryngology, 2022.

ATLAS All-in-One - 35 ingredients, 4 capsules, once a day.